Updated review confirms cannabidiol likely reduces seizure frequency in children with drug-resistant epilepsy

An updated systematic review of 35 studies, including four RCTs, found cannabidiol probably reduces seizure frequency in children with drug-resistant epilepsy but increases gastrointestinal side effects.

Elliott, Jesse et al.·Seizure·2020·Strong EvidenceSystematic Review
RTHC-02531Systematic ReviewStrong Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Systematic Review
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Data from both RCTs and non-randomized studies suggest cannabidiol reduces seizure frequency as adjunctive treatment, though RCTs showed no statistically significant difference for seizure freedom, quality of life, or sleep disruption compared to placebo.

Key Numbers

35 studies analyzed (12 new since April 2018), including 4 RCTs. Seizure freedom RR: 6.77 (95% CI 0.36-128.38). Quality of life MD: 0.6 (95% CI -2.6 to 3.9).

How They Did This

Updated systematic review searching for studies published through May 2019. Included RCTs and non-randomized studies of cannabis-based products in children with epilepsy. Four RCTs and 31 non-randomized studies were analyzed.

Why This Research Matters

This updated review adds 12 new studies since 2018 and provides the most comprehensive evidence summary for cannabidiol in pediatric epilepsy, confirming earlier findings of seizure frequency reduction.

The Bigger Picture

While CBD does not appear to achieve seizure freedom more than placebo, its ability to reduce seizure frequency in treatment-resistant cases represents a meaningful option for families who have exhausted conventional therapies.

What This Study Doesn't Tell Us

Wide confidence intervals for seizure freedom reflect small sample sizes. Most studies used CBD as adjunctive treatment, making it difficult to isolate its independent effect. Increased GI adverse events are a concern.

Questions This Raises

  • ?What is the optimal CBD dosing for pediatric epilepsy?
  • ?Can the gastrointestinal side effects be managed to improve tolerability?
  • ?Does long-term CBD use maintain its seizure-reducing effects?

Trust & Context

Key Stat:
35 studies reviewed, including 4 RCTs
Evidence Grade:
Strong: systematic review incorporating multiple RCTs and non-randomized studies with structured methodology.
Study Age:
Published in 2020 in Seizure.
Original Title:
Cannabis-based products for pediatric epilepsy: An updated systematic review.
Published In:
Seizure, 75, 18-22 (2020)
Database ID:
RTHC-02531

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Analyzes all available research on a topic using a structured method.

What do these levels mean? →

Frequently Asked Questions

Does CBD cure epilepsy in children?

No. The review found CBD did not significantly increase seizure freedom compared to placebo. However, it appears to reduce how often seizures occur, which can still be meaningful for children with treatment-resistant epilepsy.

What were the side effects?

Children taking CBD had an increased risk of gastrointestinal adverse events compared to placebo. The review noted this as a consistent finding across studies.

Read More on RethinkTHC

Cite This Study

RTHC-02531·https://rethinkthc.com/research/RTHC-02531

APA

Elliott, Jesse; DeJean, Deirdre; Clifford, Tammy; Coyle, Doug; Potter, Beth K; Skidmore, Becky; Alexander, Christine; Repetski, Alexander E; Shukla, Vijay; McCoy, Bláthnaid; Wells, George A. (2020). Cannabis-based products for pediatric epilepsy: An updated systematic review.. Seizure, 75, 18-22. https://doi.org/10.1016/j.seizure.2019.12.006

MLA

Elliott, Jesse, et al. "Cannabis-based products for pediatric epilepsy: An updated systematic review.." Seizure, 2020. https://doi.org/10.1016/j.seizure.2019.12.006

RethinkTHC

RethinkTHC Research Database. "Cannabis-based products for pediatric epilepsy: An updated s..." RTHC-02531. Retrieved from https://rethinkthc.com/research/elliott-2020-cannabisbased-products-for-pediatric

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.